Scientists at King’s College London have developed an innovative IgE antibody therapy that activates the immune system to ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

Immunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being ...

Mucormycosis, a fungus infection caused by Mucorales, has a high mortality rates in those with weakened immune systems and ...

Oxford BioTherapeutics (OBT) has entered a multi-year partnership with Roche to discover antibody-based therapeutics for ...

Immunotherapy, or antibody treatment that activates the patient’s own immune system against cancer, is increasingly being ...

London: Immunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being studied as an alternative to chemotherapy and radiotherapy.

A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer in a first-in-human trial. These results were presented at ...

Oxford BioTherapeutics (OBT), a clinical-stage oncology firm, has announced a long-term partnership with Roche ...

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.